{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:35:33Z","timestamp":1793396133891,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["10835"],"award-info":[{"award-number":["10835"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["10835"],"award-info":[{"award-number":["10835"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Combination therapies targeting malignancies aim to increase treatment efficacy and reduce toxicity. Hypomethylating drug 5-Aza-2\u2019-deoxycytidine (5-Aza-2\u2019) enhances transcription of tumor suppressor genes and induces replication errors via entrapment of DNMT1, yielding DNA-protein crosslinks. Post-translational modification by SUMO plays major roles in the DNA damage response and is required for degradation of entrapped DNMT1. Here, we combine SUMOylation inhibitor TAK981 and DNA-hypomethylating agent 5-Aza-2\u2019-deoxycytidine to improve treatment of MYC driven hematopoietic malignancies, since MYC overexpressing tumors are sensitive to SUMOylation inhibition. We studied the classical MYC driven malignancy Burkitt lymphoma, as well as diffuse large B-cell lymphoma (DLBCL) with and without MYC translocation. SUMO inhibition prolonged the entrapment of DNMT1 to DNA, resulting in DNA damage. An increase in DNA damage was observed in cells co-treated with TAK981 and 5-Aza-2\u2019. Both drugs synergized to reduce cell proliferation in vitro in a B cell lymphoma cell panel, including Burkitt lymphoma and DLBCL. In vivo experiments combining TAK981 (25\u2009mg\/kg) and 5-Aza-2\u2019 (2.5\u2009mg\/kg) showed a significant reduction in outgrowth of Burkitt lymphoma in an orthotopic xenograft model. Our results demonstrate the potential of tailored combination of drugs, based on insight in molecular mechanisms, to improve the efficacy of cancer therapies.<\/jats:p>","DOI":"10.1038\/s41375-023-01838-8","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T12:49:47Z","timestamp":1676983787000},"page":"864-876","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0997-6267","authenticated-orcid":false,"given":"Jessie S.","family":"Kroonen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4957-2424","authenticated-orcid":false,"given":"Ilona J.","family":"de Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis F. G.","family":"Remst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9861-7276","authenticated-orcid":false,"given":"Anne K.","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6320-9133","authenticated-orcid":false,"given":"Mirjam H. M.","family":"Heemskerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7989-0493","authenticated-orcid":false,"given":"Alfred C. O.","family":"Vertegaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"1838_CR1","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"RB Mokhtari","year":"2017","unstructured":"Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget 2017;8:38022\u201343.","journal-title":"Oncotarget"},{"key":"1838_CR2","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1200\/JCO.2007.11.9362","volume":"26","author":"KS Albain","year":"2008","unstructured":"Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26:3950\u20137.","journal-title":"J Clin Oncol"},{"key":"1838_CR3","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrg.2016.93","volume":"17","author":"PA Jones","year":"2016","unstructured":"Jones PA, Issa JPJ, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016;17:630\u201341.","journal-title":"Nat Rev Genet"},{"key":"1838_CR4","doi-asserted-by":"crossref","unstructured":"Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, et al. Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019;4:62.","DOI":"10.1038\/s41392-019-0095-0"},{"key":"1838_CR5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cell.2013.03.008","volume":"153","author":"H Shen","year":"2013","unstructured":"Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell 2013;153:38\u201355.","journal-title":"Cell"},{"key":"1838_CR6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V","volume":"183","author":"RL Momparler","year":"2000","unstructured":"Momparler RL, Bovenzi V. DNA Methylation and Cancer. J Cell Physiol. 2000;183:145\u201354.","journal-title":"J Cell Physiol"},{"key":"1838_CR7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/hon.694","volume":"20","author":"CS Chim","year":"2002","unstructured":"Chim CS, Liang R, Kwong YL. Hypermethylation of gene promoters in hematological neoplasia. Hematol Oncol. 2002;20:167\u201376.","journal-title":"Hematol Oncol"},{"key":"1838_CR8","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood.V97.5.1172","volume":"97","author":"SI Mizuno","year":"2001","unstructured":"Mizuno SI, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y, et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 2001;97:1172\u20139.","journal-title":"Blood"},{"key":"1838_CR9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2147\/IJWH.S133441","volume":"9","author":"CJ Piyathilake","year":"2017","unstructured":"Piyathilake CJ, Badiga S, Borak SG, Weragoda J, Bae S, Matthews R, et al. A higher degree of expression of DNA methyl transferase 1 in cervical cancer is associated with poor survival outcome. Int J Women\u2019s Health. 2017;9:413.","journal-title":"Int J Women\u2019s Health"},{"key":"1838_CR10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","volume":"20","author":"PA Jones","year":"1980","unstructured":"Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85\u201393.","journal-title":"Cell"},{"key":"1838_CR11","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","volume":"29","author":"T Pr\u00e9bet","year":"2011","unstructured":"Pr\u00e9bet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29:3322\u20137.","journal-title":"J Clin Oncol"},{"key":"1838_CR12","doi-asserted-by":"crossref","first-page":"e23372","DOI":"10.1371\/journal.pone.0023372","volume":"6","author":"T Qin","year":"2011","unstructured":"Qin T, Castoro R, el Ahdab S, Jelinek J, Wang X, Si J, et al. Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome. PLoS One. 2011;6:e23372.","journal-title":"PLoS One"},{"key":"1838_CR13","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1002\/cncr.23463","volume":"112","author":"E Jabbour","year":"2008","unstructured":"Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H. Evolution of Decitabine Development: Accomplishments, Ongoing Investigations, and Future Strategies. Cancer 2008;112:2341.","journal-title":"Cancer"},{"key":"1838_CR14","doi-asserted-by":"crossref","unstructured":"Borgermann N, Ackermann L, Schwertman P, Hendriks IA, Thijssen K, Liu JC, et al. SUMOylation promotes protective responses to DNA\u2010protein crosslinks. EMBO J. 2019;38:e101496.","DOI":"10.15252\/embj.2019101496"},{"key":"1838_CR15","doi-asserted-by":"crossref","first-page":"e107413","DOI":"10.15252\/embj.2020107413","volume":"40","author":"JCY Liu","year":"2021","unstructured":"Liu JCY, K\u00fchbacher U, Larsen NB, Borgermann N, Garvanska DH, Hendriks IA, et al. Mechanism and function of DNA replication\u2010independent DNA\u2010protein crosslink repair via the SUMO\u2010RNF4 pathway. EMBO J. 2021;40:e107413.","journal-title":"EMBO J"},{"key":"1838_CR16","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1021\/acs.jmedchem.0c01491","volume":"64","author":"SP Langston","year":"2021","unstructured":"Langston SP, Grossman S, England D, Afroze R, Bence N, Bowman D, et al. Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer. J Med Chem. 2021;64:2501\u201320.","journal-title":"J Med Chem"},{"key":"1838_CR17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev-biochem-061909-093311","volume":"82","author":"A Flotho","year":"2013","unstructured":"Flotho A, Melchior F. Sumoylation: A Regulatory Protein Modification in Health and Disease. Annu Rev Biochem. 2013;82:357\u201385.","journal-title":"Annu Rev Biochem"},{"key":"1838_CR18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41580-022-00500-y","volume":"23","author":"ACO Vertegaal","year":"2022","unstructured":"Vertegaal ACO. Signalling mechanisms and cellular functions of SUMO. Nat Rev Mol Cell Biol. 2022;23:715\u201331.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1838_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules26040828","volume":"26","author":"M Boulanger","year":"2021","unstructured":"Boulanger M, Chakraborty M, Temp\u00e9 D, Piechaczyk M, Bossis G. Sumo and transcriptional regulation: The lessons of large-scale proteomic, modifomic and genomic studies. Molecules 2021;26:1\u201339.","journal-title":"Molecules"},{"key":"1838_CR20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.trecan.2020.11.009","volume":"7","author":"JS Kroonen","year":"2021","unstructured":"Kroonen JS, Vertegaal ACO. Targeting SUMO Signaling to Wrestle Cancer. Trends Cancer. 2021;7:496\u2013510.","journal-title":"Trends Cancer"},{"key":"1838_CR21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.chembiol.2019.02.006","volume":"26","author":"RS Magin","year":"2019","unstructured":"Magin RS, Doherty LM, Buhrlage SJ. Discovery of a First-In-Class Covalent Allosteric Inhibitor of SUMO E1 Activating Enzyme. Cell Chem Biol. 2019;26:153\u20135.","journal-title":"Cell Chem Biol"},{"key":"1838_CR22","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/nchembio.2463","volume":"13","author":"X He","year":"2017","unstructured":"He X, Riceberg J, Soucy T, Koenig E, Minissale J, Gallery M, et al. Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor. Nat Chem Biol. 2017;13:1164\u201371.","journal-title":"Nat Chem Biol"},{"key":"1838_CR23","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1136\/gutjnl-2021-324834","volume":"71","author":"S Kumar","year":"2022","unstructured":"Kumar S, Schoonderwoerd MJA, Kroonen JS, de Graaf IJ, Sluijter M, Ruano D, et al. Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model. Gut 2022;71:2266\u201383.","journal-title":"Gut"},{"key":"1838_CR24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc.2016.143","volume":"17","author":"JS Seeler","year":"2017","unstructured":"Seeler JS, Dejean A. SUMO and the robustness of cancer. Nat Rev Cancer. 2017;17:184\u201397.","journal-title":"Nat Rev Cancer"},{"key":"1838_CR25","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.tibs.2015.09.006","volume":"40","author":"K Eifler","year":"2015","unstructured":"Eifler K, Vertegaal ACO. SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer. Trends Biochem Sci. 2015;40:779\u201393.","journal-title":"Trends Biochem Sci"},{"key":"1838_CR26","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood-2014-06-584524","volume":"124","author":"A Hoellein","year":"2014","unstructured":"Hoellein A, Fallahi M, Schoeffmann S, Steidle S, Schaub FX, Rudelius M, et al. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Blood 2014;124:2081\u201390.","journal-title":"Blood"},{"key":"1838_CR27","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1126\/science.1212728","volume":"335","author":"JD Kessler","year":"2012","unstructured":"Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 2012;335:348\u201353.","journal-title":"Science"},{"key":"1838_CR28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/asheducation-2014.1.107","volume":"1","author":"K Dunleavy","year":"2014","unstructured":"Dunleavy K. Double-hit lymphomas: current paradigms and novel treatment approaches. Hematology 2014;1:107\u201312.","journal-title":"Hematology"},{"key":"1838_CR29","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood-2015-05-647602","volume":"126","author":"C Copie-Bergman","year":"2015","unstructured":"Copie-Bergman C, Cuill\u00ec ere-Dartigues P, Baia M, Briere J, Delarue R, Canioni D, et al. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA\/LYSA study. Blood. 2015;126:2466\u201374.","journal-title":"Blood"},{"key":"1838_CR30","doi-asserted-by":"crossref","first-page":"878","DOI":"10.15252\/embr.201438534","volume":"15","author":"L Wang","year":"2014","unstructured":"Wang L, Wansleeben C, Zhao S, Miao P, Paschen W, Yang W. SUMO2 is essential while SUMO 3 is dispensable for mouse embryonic development. EMBO Rep. 2014;15:878\u201385.","journal-title":"EMBO Rep"},{"key":"1838_CR31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-1-4939-6358-4_13","volume":"1475","author":"IA Hendriks","year":"2016","unstructured":"Hendriks IA, Vertegaal ACO. Label-free identification and quantification of SUMO target proteins. Methods Mol Biol. 2016;1475:171\u201393.","journal-title":"Methods Mol Biol"},{"key":"1838_CR32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/br.20.4.243-258.1956","volume":"20","author":"CI Bliss","year":"1956","unstructured":"Bliss CI. The calculation of microbial assays. Bacteriol Rev. 1956;20:243\u201358.","journal-title":"Bacteriol Rev"},{"key":"1838_CR33","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.celrep.2016.06.015","volume":"16","author":"JN Bonner","year":"2016","unstructured":"Bonner JN, Choi K, Xue X, Torres NP, Szakal B, Wei L, et al. Smc5\/6 Mediated Sumoylation of the Sgs1-Top3-Rmi1 Complex Promotes Removal of Recombination Intermediates. Cell Rep. 2016;16:368\u201378.","journal-title":"Cell Rep"},{"key":"1838_CR34","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1101\/gad.278275.116","volume":"30","author":"M Berm\u00fadez-L\u00f3pez","year":"2016","unstructured":"Berm\u00fadez-L\u00f3pez M, Villoria MT, Esteras M, Jarmuz A, Torres-Rosell J, Clemente-Blanco A, et al. Sgs1\u2019s roles in DNA end resection, HJ dissolution, and crossover suppression require a two-step SUMO regulation dependent on Smc5\/6. Genes Dev. 2016;30:1339\u201356.","journal-title":"Genes Dev"},{"key":"1838_CR35","doi-asserted-by":"crossref","first-page":"e1526","DOI":"10.1002\/onco.13829","volume":"26","author":"MR Toh","year":"2021","unstructured":"Toh MR, Ngeow J. Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications. Oncologist. 2021;26:e1526\u201337.","journal-title":"Oncologist"},{"key":"1838_CR36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrm.2016.58","volume":"17","author":"P Schwertman","year":"2016","unstructured":"Schwertman P, Bekker-Jensen S, Mailand N. Regulation of DNA double-strand break repair by ubiquitin and ubiquitin-like modifiers. Nat Rev Mol Cell Biol. 2016;17:379\u201394.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1838_CR37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13046-021-02226-9","volume":"41","author":"L Du","year":"2022","unstructured":"Du L, Liu W, Aldana-Masangkay G, Pozhitkov A, Pichiorri F, Chen Y, et al. SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma. J Exp Clin Cancer Res. 2022;41:8.","journal-title":"J Exp Clin Cancer Res"},{"key":"1838_CR38","doi-asserted-by":"publisher","unstructured":"Du L, Liu W, Pichiorri F, Rosen ST. SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide. Cancer Gene Ther. 2022; https:\/\/doi.org\/10.1038\/s41417-022-00450-9.","DOI":"10.1038\/s41417-022-00450-9"},{"key":"1838_CR39","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1182\/blood.V118.21.578.578","volume":"118","author":"PG Smith","year":"2011","unstructured":"Smith PG, Traore T, Grossman S, Narayanan U, Carew JS, Lublinksky A, et al. Azacitidine\/Decitabine Synergism with the NEDD8-Activating Enzyme Inhibitor MLN4924 in Pre-Clinical AML Models. Blood. 2011;118:578.","journal-title":"Blood."},{"key":"1838_CR40","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood-2017-09-805895","volume":"131","author":"RT Swords","year":"2018","unstructured":"Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, et al. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood. 2018;131:1415\u201324.","journal-title":"Blood."},{"key":"1838_CR41","doi-asserted-by":"crossref","unstructured":"Winkle M, Tayari MM, Kok K, Duns G, Grot N, Kazimierska M, et al. The lncRNA KTN1-AS1 co-regulates a variety of Myc-target genes and enhances proliferation of Burkitt lymphoma cells. Hum Mol Genet. 2022;31:4193\u2013206.","DOI":"10.1093\/hmg\/ddac159"},{"key":"1838_CR42","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76603-3","volume":"10","author":"J Goedhart","year":"2020","unstructured":"Goedhart J, Luijsterburg MS. VolcaNoseR is a web app for creating, exploring, labeling and sharing volcano plots. Sci Rep. 2020;10:20560.","journal-title":"Sci Rep."},{"key":"1838_CR43","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498\u2013504.","journal-title":"Genome Res"},{"key":"1838_CR44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ijc.2910100108","volume":"10","author":"G Klein","year":"1972","unstructured":"Klein G, Dombos L. Gothoskar Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus. Int J Cancer. 1972;10:44\u201357.","journal-title":"Int J Cancer"},{"key":"1838_CR45","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ijc.2910180513","volume":"18","author":"G Klein","year":"1976","unstructured":"Klein G, Zeuthen J, Terasaki P, Billing R, Honig R, Jondal M, et al. Inducibility of the Epstein-Barr virus (EBV) cycle and surface marker properties of EBV-negative lymphoma lines and their in vitro EBV-converted sublines. Int J Cancer 1976;18:639\u201352.","journal-title":"Int J Cancer"},{"key":"1838_CR46","first-page":"465","volume":"64","author":"IT Magrath","year":"1980","unstructured":"Magrath IT, Pizzo PA, Whang-Peng J, Douglass EC, Alabaster O, Gerber P, et al. Characterization of Lymphoma-Derived Cell Lines: Comparison of Cell Lines Positive and Negative for Epstein-Barr Virus Nuclear Antigen. I. Physical, Cytogenetic, and Growth Characteristics. J Natl Cancer Inst. 1980;64:465\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"1838_CR47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ijc.2910190105","volume":"19","author":"HI Ben-bassat","year":"1977","unstructured":"Ben-bassat HI, Goldblum N, Mitrani S, Goldblum T, Yoffey Maimon M, Cohen JM, et al. Establishment in continuous culture of a new type of lymphocyte from a \u201cBurkitt like\u201d malignant lymphoma (line D.G.-75). Int J Cancer 1977;19:27\u201333.","journal-title":"Int J Cancer"},{"key":"1838_CR48","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.tranon.2018.07.007","volume":"11","author":"W Deng","year":"2018","unstructured":"Deng W, Clipson A, Liu H, Huang Y, Dobson R, Wang M, et al. Variable Responses of MYC Translocation Positive Lymphoma Cell Lines To Different Combinations of Novel Agents: Impact of BCL2 Family Protein Expression. Transl Oncol. 2018;11:1147\u201354.","journal-title":"Transl Oncol"},{"key":"1838_CR49","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3109\/10428199509059672","volume":"19","author":"H Chang","year":"1995","unstructured":"Chang H, Blondal JA, Benchimol S, Minden MD, Messner HA, Benchimol SAM, et al. p53 Mutations, c-myc and bcl-2 Rearrangements in Human Non-Hodgkin\u2019s Lymphoma Cell Lines. Leuk Lymphoma. 1995;19:165\u201372.","journal-title":"Leuk Lymphoma"},{"key":"1838_CR50","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1080\/1042819021000032917","volume":"43","author":"RM Amini","year":"2009","unstructured":"Amini RM, Berglund M, Rosenquist R, von Heideman A, Lagercrantz S, Thunberg U, et al. A Novel B-cell Line (U-2932) Established from a Patient with Diffuse Large B-cell Lymphoma Following Hodgkin Lymphoma. Leuk Lymphoma. 2009;43:2179\u201389.","journal-title":"Leuk Lymphoma"},{"key":"1838_CR51","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ijc.2910390116","volume":"39","author":"KH Th\u2019ng","year":"1987","unstructured":"Th\u2019ng KH, Garewal G, Kearney L, Rassool F, Melo JV, White H, et al. Establishment and characterization of three new malignant lymphoid cell lines. Int J Cancer. 1987;39:89\u201393.","journal-title":"Int J Cancer"},{"key":"1838_CR52","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3109\/10428194.2015.1108414","volume":"57","author":"HG Drexler","year":"2016","unstructured":"Drexler HG, Eberth S, Nagel S, MacLeod RAF. Malignant hematopoietic cell lines: In vitro models for double-hit B-cell lymphomas. Leuk Lymphoma. 2016;57:1015\u201320.","journal-title":"Leuk Lymphoma"},{"key":"1838_CR53","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0165-4608(85)90186-4","volume":"14","author":"BKMC Hecht","year":"1985","unstructured":"Hecht BKMC, Epstein AL, Berger CS, Kaplan HS, Hecht F. Histiocytic lymphoma cell lines: Immunologic and cytogenetic studies. Cancer Genet Cytogenet. 1985;14:205\u201318.","journal-title":"Cancer Genet Cytogenet"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01838-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01838-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01838-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T08:59:57Z","timestamp":1701939597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01838-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1838"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-01838-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"assertion":[{"value":"11 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}